3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Endocrine
2
CNS
2
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
gallium Ga 68 dotatate
3
belzutifan
2
spartalizumab
1
Magnetic Resonance Spectroscopy
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled